Özduran G.Becer E.Vatansever H.S.Yücecan S.2024-07-222024-07-22202201616412http://akademikarsiv.cbu.edu.tr:4000/handle/123456789/12977Objectives: The aim of the study was to establish an in vitro Parkinson’s disease (PD) model and to investigate the cell viability, anti-inflammatory, anti-apoptotic and neuroprotective effects of catechin and EGCG in SK-N-AS and in vitro PD model cells. Method: SK-N-AS human neuroblastoma cells were used. To develop an in vitro PD model, SK-N-AS cells were exposed to 6-hydroxydopamine. Model control was performed after ELISA analysis of dopamine and α-synuclein levels in the culture medium. Catechin and EGCG were administered to SK-N-AS and in vitro PD model cells. Cell viability was measured using MTT assay and trypan blue staining. Anti-inflammatory and anti-apoptotic activities of catechin and EGCG were investigated by indirect immunocytochemistry using anti-TNF-α, anti-IL-1β and anti-caspase-3. Results: After 24 hours of 6-hydroxydopamine administration at 50 μM, higher αlfa-synuclein and lower dopamine levels were found in PD model than SK-N-AS cells. Cell viability was similar between SK-N-AS and in vitro PD model cells. Treatment with both bioactive components increased cell viability of in vitro PD model cells. Caspase-3 immunoreactivity was significantly reduced in SK-N-AS and PD model cells after EGCG administration, while it was decreased only in PD model cells after catechin administration. IL-1β staining intensity weakened after catechin administration in PD model cells, after EGCG administration in SK-N-AS cells. TNF-α staining intensity was similar in both cells. Conclusion: Catechin and EGCG increased cell viability in PD model neuron cells. Both components showed anti-apoptotic and anti-inflammatory effects. Catechin may be more effective in preventing damage to neurons PD. © 2022 Informa UK Limited, trading as Taylor & Francis Group.EnglishAnti-Inflammatory AgentsApoptosisCatechinCell SurvivalDopamineHumansNeuroprotective AgentsOxidopamineParkinson DiseaseTumor Necrosis Factor Inhibitors3 (4,5 dimethyl 2 thiazolyl) 2,5 diphenyltetrazolium bromidealpha synucleinc0567caspase 3catechindopaminee4268epigallocatechin gallateh4381interleukin 1betam2128oxidopaminesuperoxide dismutaset8532triton x 100trypan bluetumor necrosis factorantiinflammatory agentcatechinneuroprotective agentoxidopaminetumor necrosis factor inhibitorantiapoptotic activityantiinflammatory activityArticlecell culturecell viabilityclinical evaluationcontrolled studydopaminergic nerve cellenzyme linked immunosorbent assayexperimental parkinsonismhumanhuman cellimmunocytochemistryimmunoreactivityin vitro studymorphologyMTT assaynerve cellneuroblastomaneuroblastoma cellneuroprotectionSK-N-AS cell linestatistical analysisapoptosiscell survivalParkinson diseaseArticle10.1080/01616412.2021.2024715